Internet Archive Scholar

Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort

L. Guglielmetti, D. Le Du, M. Jachym, B. Henry, D. Martin, E. Caumes, N. Veziris, N. Metivier, J. Robert, C. Andrejak, C. Bernard, F. Brossier (+25 others)
2014 Clinical Infectious Diseases  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (159.3 kB)
https://web.archive.org/web/20170812060354/https://www.ghdonline.org/uploads/MDR_TB1.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL. The file type is application/pdf.

Background. Bedaquiline is a new antibiotic that was approved for the treatment of multidrug-resistant (MDR) tuberculosis. We aimed to evaluate the short-term microbiological efficacy and the tolerability profile of bedaquiline. Methods. We performed a retrospective cohort study among patients with MDR tuberculosis receiving bedaquiline for compassionate use between January 2010 and July 2013 and evaluated at 6 months of bedaquiline treatment. Results. A total of 35 patients with MDR
more » ... s were included in the study. Nineteen (54%) had extensively drug-resistant (XDR) tuberculosis, and 14 (40%) had isolates resistant to fluoroquinolones (Fqs) or second-line injectables. Bedaquiline was associated with a median of 4 (range, 2-5) other drugs, including linezolid in 33 (94%) cases. At 6 months of bedaquiline treatment, culture conversion was achieved in 28 of 29 (97%) cases with culture-positive pulmonary tuberculosis at bedaquiline initiation. Median time to culture conversion was 85 days (range, 8-235 days). Variables independently associated with culture conversion were treatment with a Fq (P = .01), absence of lung cavities (P < .001), and absence of hepatitis C virus infection (P = .001). A total of 7 patients (20%) experienced a ≥60-ms increase in QT interval, leading to bedaquiline discontinuation in 2 (6%) cases. Severe liver enzyme elevation occurred in 2 patients (6%). During the study period, 1 death (3%) occurred and was reported as unrelated to tuberculosis or antituberculosis treatment. Conclusions. The use of bedaquiline combined with other active drugs has the potential to achieve high culture conversion rates in complicated MDR and XDR tuberculosis cases, with a reassuring safety profile at 6 months of treatment.
doi:10.1093/cid/ciu786 pmid:25320286 fatcat:prvmkcbbcvbwzkitrmo6vf522q
Citation

L. Guglielmetti, D. Le Du, M. Jachym, B. Henry, D. Martin, E. Caumes, N. Veziris, N. Metivier, J. Robert, C. Andrejak, C. Bernard, F. Brossier, K. Chadelat, B. Dautzenberg, V. Jarlier, L. Raskine, B. Rivoire, N. Veziris, C. Appere, P. Assouline, R. Borie, L. Boukari, M. Caseris, E. Caumes, Y. Douadi, J. Dumoulin, C. Duval, J. F. Faucher, S. Gallien, C. Godet, J. Le Grusse, A. Lopes, J. L. Meynard, J. M. Naccache, B. Philippe, C. Richaud, H. Saad. "Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort." Clinical Infectious Diseases 60.2 (2014) 188-194